[
  {
    "ts": null,
    "headline": "Ariel Focus Fund Q4 2025 Portfolio Review",
    "summary": "Barrick Mining Corporationâs solid liquidity supports its commitment to shareholder returns, reflected in increased share repurchases and a raise in its quarterly dividend.",
    "url": "https://finnhub.io/api/news?id=873a7f66df66d1438331af4cf8534835cefafabb5596e0477b2b6b248b7d9d8a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769942100,
      "headline": "Ariel Focus Fund Q4 2025 Portfolio Review",
      "id": 138324333,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2208603114/image_2208603114.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Barrick Mining Corporationâs solid liquidity supports its commitment to shareholder returns, reflected in increased share repurchases and a raise in its quarterly dividend.",
      "url": "https://finnhub.io/api/news?id=873a7f66df66d1438331af4cf8534835cefafabb5596e0477b2b6b248b7d9d8a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson’s Myeloma Approval And What It May Mean For JNJ Stock",
    "summary": "Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This decision expands treatment options for a specific group of multiple myeloma patients. For Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex...",
    "url": "https://finnhub.io/api/news?id=aee07fcbdfe494782f51fb41bd8fbacc567e7a5022612d27f9c07d8c3838070f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769922420,
      "headline": "Johnson & Johnson’s Myeloma Approval And What It May Mean For JNJ Stock",
      "id": 138321518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This decision expands treatment options for a specific group of multiple myeloma patients. For Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex...",
      "url": "https://finnhub.io/api/news?id=aee07fcbdfe494782f51fb41bd8fbacc567e7a5022612d27f9c07d8c3838070f"
    }
  }
]